Tom Hudson, AbbVie SVP of R&D and CSO
AbbVie adds to its neuro pipeline with a $1B buyout deal, bolting on a new drug aimed at Alzheimer’s
AbbVie is beefing up its neuro pipeline with a small biotech buyout that adds a new approach to cognitive decline in Alzheimer’s and other CNS …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
